Skip to main content

Advertisement

Table 2 Median concentrations in NAF of uPA and PAI-1 (pg/mg), PGE2 (ng/mL) and in plasma of celecoxib (ng/mL) based on celecoxib dose and menopausal status1

From: uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

Dose N Baseline After Tx Δ P value Celecoxib
200 mg bid 2       
uPA       
Overall 9 422.0 375.2 -19.6 0.10 346.0
Premen 2 133.6 130.1 -3.5 0.50 231.8
Postmen 7 645.1 402.4 -57.0 0.22 728.2
PAI-1       
Overall 8 709.0 194.4 -26.7 0.56 288.1
Premen 2 2672 1821 -850.8 0.99 231.8
Postmen 6 709.0 194.4 -26.7 0.99 479.1
PGE 2       
Overall 9 8.71 13.34 -1.04 0.91 346.0
Premen 2 25.45 25.96 0.52 0.99 231.8
Postmen 7 8.71 9.80 -1.04 0.81 728.2
400 mg bid 2       
uPA       
Overall 11 372.6 321.6 22.0 0.46 184.0
Premen 5 372.6 321.6 11.0 0.99 0
Postmen 6 409.1 382.4 28.2 0.31 1141.8
PAI-1       
Overall 5 2401 827.8 0 0.62 156.8
Premen 1 281.6 344.7 63.1 - 0
Postmen 4 2416 1437 -801.7 0.50 789.9
PGE 2       
Overall 11 12.32 13.45 -1.77 0.96 184.2
Premen 5 12.32 51.24 21.95 0.31 0
Postmen 6 14.79 13.22 -6.41 0.16 1141.8
  1. 1: N: sample size; NAF: nipple aspirate fluid. NS: not significant. Units reflect pg uPA or PAI-1/mg total protein. Δ reflects the median of the change measured in each subject (after treatment value – before treatment value) due to treatment. Celecoxib level is from plasma collected after treatment.
  2. 2: Not all NAF samples were sufficient to analyze all proteins; bid: twice daily; premen: premenopausal; postmen: postmenopausal